Areca Bio provides an AI‑driven immunogenicity prediction engine that identifies tumor neoantigens with three times the accuracy of existing benchmarks, enabling faster design of personalized cancer vaccines. The platform combines machine learning with deep immunological expertise to analyze patient tumor genomics, generate optimal vaccine candidates, and shorten development cycles for biopharma companies and research institutions. Its precision targeting aims to maximize immune response while reducing off‑target effects.
Funding
Funding not disclosed
Founders
Product
Problem
Identifying tumor neoantigens that will elicit a strong and specific immune response is a complex, data‑intensive task, and existing prediction methods often miss optimal targets, leading to longer development cycles and higher risk of off‑target effects in personalized cancer vaccines.
Solution
Areca Bio offers an AI‑driven immunogenicity prediction platform that analyzes comprehensive tumor genomic and biomolecular signals to pinpoint neoantigens with three times the accuracy of industry benchmarks. The engine, named NeoPrecis, integrates data on MHC binding, T‑cell receptor cross‑reactivity, HLA alterations, dual CD4⁺/CD8⁺ presentation, viral similarity, evolutionary immune signals, and germline variation. By modeling the full complexity of tumor‑immune interactions over time, the platform accelerates the vaccine design workflow, reducing the interval from genomic sequencing to candidate selection. The resulting personalized vaccine designs aim to maximize therapeutic immune response while minimizing off‑target activity, supporting biopharma partners and research institutions in developing next‑generation cancer immunotherapies.
Target Audience
Primary customers are biopharma companies and research institutions developing personalized cancer vaccines, as well as clinicians exploring experimental immunotherapy options for individual patients.
Features
- Multi‑signal AI engine (NeoPrecis) that incorporates MHC binding, TCR cross‑reactivity, HLA damage, CD4⁺/CD8⁺ prediction, viral similarity, evolutionary immune cues, and germline variation
- Predictive accuracy reported at 90%, roughly 3× higher than conventional methods
- End‑to‑end computational pipeline that shortens the time from tumor genomic data to neoantigen candidate identification
- Dual CD4⁺ and CD8⁺ epitope prediction to enhance both helper and cytotoxic T‑cell responses
- Cloud‑based platform enabling integration with biopharma and research workflows for rapid vaccine design